Glucocorticoids are among the many most generally used anti-inflammatory and immunosuppressive medicine. Nevertheless, their extended administration is related to a variety of antagonistic unwanted side effects together with long-lasting immunosuppression. On this research, we aimed to encapsulate two generally used glucocorticoids with totally different efficiency and length, hydrocortisone and dexamethasone, into poly(lactic-co-glycolic acid) (PLGA) nanoparticles with the objective to modulate inflammatory gene expression in a delivery-dependent method. We evaluated their anti-inflammatory properties in two in vitro fashions various the timing of remedy administration primarily based on lipopolysaccharide M1-polarized macrophages, key effectors of the innate immune system. Our outcomes demonstrated that, for each methods, drug-loaded nanoparticles considerably decreased the expression of interleukin-6, a pro-inflammatory cytokine, in comparison with the free medicine. Nevertheless, in one of many methods, whereas free medicine induced upregulation of interleukin-10, a key anti-inflammatory cytokine, no such impact was noticed with the nanoparticle-based formulations. Total, these outcomes reveal that PLGA nanoparticles allow sustained glucocorticoid supply and modulate inflammatory gene expression in activated macrophages in a delivery- and timing-dependent method, offering comparative perception into how glucocorticoid supply by way of PLGA nanoparticles shapes inflammatory gene regulation relying on remedy timing and highlighting the significance of in vitro mannequin design.
